Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (631-640 of 1,095) with videos related to

Pageof 110
Sort By:
Antiviral Therapy|August 28, 2015
Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)Christophe Hézode, Laurent Alric, Ashley Brown, et al.
Digestive Diseases and Sciences|December 24, 2014
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infectionMaria Buti, Naoky Tsai, Joerg Petersen, et al.
Lung Cancer (Amsterdam, Netherlands)|April 15, 2015
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patientsSebastiano Buti, Paola Bordi, Marcello Tiseo, et al.
Journal of Hepatology|December 13, 2023
Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II studyLise Retat, Laura Webber, Peter Jepsen, et al.
Viruses|July 29, 2023
Community Strategy for Hepatitis B, C, and D Screening and Linkage to Care in Mongolians Living in SpainAdriana Palom, Edurne Almandoz, Antonio Madejón, et al.
Anticancer Research|February 27, 2022
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?Chiara Ciccarese, Roberto Iacovelli, Sebastiano Buti, et al.
Plos One|January 6, 2017
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseTarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Plant Physiology and Biochemistry : PPB|January 18, 2025
Coding and non-coding transcripts modulated by transparent and blue PET micro-nanoplastics in Arabidopsis thalianaMarco Dainelli, Ilaria Colzi, Domenico Giosa, et al.
BMC Cancer|June 24, 2024
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study)Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, et al.
Gut|November 5, 2025
Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT studyPatrick T F Kennedy, Scott Fung, Maria Buti, et al.
Pageof 110

Showing results (631-640 of 1,095) with videos related to

Sort By:
Pageof 110
Antiviral Therapy|August 28, 2015
Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)Christophe Hézode, Laurent Alric, Ashley Brown, et al.
Digestive Diseases and Sciences|December 24, 2014
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infectionMaria Buti, Naoky Tsai, Joerg Petersen, et al.
Lung Cancer (Amsterdam, Netherlands)|April 15, 2015
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patientsSebastiano Buti, Paola Bordi, Marcello Tiseo, et al.
Journal of Hepatology|December 13, 2023
Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II studyLise Retat, Laura Webber, Peter Jepsen, et al.
Viruses|July 29, 2023
Community Strategy for Hepatitis B, C, and D Screening and Linkage to Care in Mongolians Living in SpainAdriana Palom, Edurne Almandoz, Antonio Madejón, et al.
Anticancer Research|February 27, 2022
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?Chiara Ciccarese, Roberto Iacovelli, Sebastiano Buti, et al.
Plos One|January 6, 2017
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic ResponseTarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
Plant Physiology and Biochemistry : PPB|January 18, 2025
Coding and non-coding transcripts modulated by transparent and blue PET micro-nanoplastics in Arabidopsis thalianaMarco Dainelli, Ilaria Colzi, Domenico Giosa, et al.
BMC Cancer|June 24, 2024
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study)Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, et al.
Gut|November 5, 2025
Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT studyPatrick T F Kennedy, Scott Fung, Maria Buti, et al.
Pageof 110